

PRIOR AUTHORIZATION POLICY

POLICY: Inflammatory Conditions – Bimzelx Prior Authorization Policy

• Bimzelx® (bimekizumab-bkzx subcutaneous injection – UCB)

REVIEW DATE: 11/01/2023

OVERVIEW

Bimzelx, an interleukin (IL)-17A and IL-17F blocker, is indicated for treatment of adults with moderate to severe **plaque psoriasis** who are candidates for systemic therapy or phototherapy.¹

Guidelines

Bimzelx is not addressed in available guidelines. Guidelines for the treatment of psoriasis with biologics from the American Academy of Dermatologists and National Psoriasis Foundation (2019) list the approved biologics that may be used as monotherapy for adults with moderate to severe disease.³

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Bimzelx. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Bimzelx as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Bimzelx to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Bimzelx is recommended in those who meet the following criteria:

FDA-Approved Indication

- **1. Plaque Psoriasis.** Approve for the duration noted if the patient meets ONE of the following criteria (A or B):
 - **A)** <u>Initial Therapy</u>. Approve for 3 months if the patient meets ALL of the following criteria (i, ii, <u>and</u> iii):
 - i. Patient is ≥ 18 years of age; AND
 - ii. Patient meets ONE of the following conditions (a or b):
 - a) Patient has tried at least at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant; OR

<u>Note</u>: Examples include methotrexate, cyclosporine, acitretin, or psoralen plus ultraviolet A light (PUVA). An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic other than the requested drug. A biosimilar of the requested biologic does not count. Refer to <u>Appendix</u> for examples of biologics used for plaque psoriasis. A patient who has already tried a biologic for psoriasis is not required to "step back" and try a traditional systemic agent for psoriasis.

- b) Patient has a contraindication to methotrexate, as determined by the prescriber; AND
- iii. The medication is prescribed by or in consultation with a dermatologist.
- **B)** Patient is Currently Receiving Bimzelx. Approve for 1 year if the patient meets ALL of the following criteria (i, ii, and iii):
 - i. Patient has been established on therapy for at least 90 days; AND Note: A patient who has received < 90 days of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
 - ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Bimzelx) in at least one of the following: estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis; AND
 - iii. Compared with baseline (prior to receiving Bimzelx), patient experienced an improvement in at least one symptom, such as decreased pain, itching, and/or burning.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Bimzelx is not recommended in the following situations:

- 1. Concurrent Use with other Biologics or with Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs). Bimzelx should not be administered in combination with a biologic used for an inflammatory condition (see Appendix for examples). Combination therapy with biologics and/or biologics + targeted synthetic DMRADs has a potential for a higher rate of adverse effects and lacks controlled trial data in support of additive efficacy.
 - <u>Note</u>: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with Bimzelx.
- 2. Inflammatory Bowel Disease (i.e., Crohn's disease, ulcerative colitis). Exacerbations of inflammatory bowel disease, in some cases serious, occurred in clinical trials involving patients treated with Bimzelx.¹
- **3.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

- 1. Bimzelx® subcutaneous injection [prescribing information]. Smyrna, GA: UCB; October 2023.
- 2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019 80(4):1029-1072.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	-	11/01/2023

APPENDIX

Biologies Adalimumab SC Products (Humira®, biosimilars) Inhibition of TNF AS, CD, JIA, PsO, PsA, RA, UC Cimzia® (certolizumab pegol SC injection) Inhibition of TNF AS, CD, nr-axSpA, PsO, PsA, RA Etanercept SC Products (Enbret®, biosimilars) Inhibition of TNF AS, CD, nr-axSpA, PsO, PsA, RA Zymfentra® (infliximab-dyyb SC injection) Inhibition of TNF AS, CD, PsO, PsA Infliximab IV Products (Remicade®, biosimilars) Inhibition of TNF AS, CD, PsO, PsA Simponi®, Simponi® Aria™ (golimumab SC injection) Inhibition of TNF AS, CD, PsO, PsA, RA, UC Componi®, Simponi® Aria™ (golimumab SC injection) Inhibition of TNF AS, CD, PsO, PsA, RA, UC Kevzara® (sarilumab IV infusion, abatacept SC injection) Inhibition of IL-6 SC formulation: AS, PJA, RA, SJIA Kevzara® (sarilumab SC injection) Inhibition of IL-1 SC formulation: JJA, PSA, RA Rituximab IV Products (Rituxan®, biosimilars) CD20-directed cytolytic antibody RA Rinere® (anakinra SC injection) Inhibition of IL-1 JJA*, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-17A PSO Bimzelx® (precion) Inhibition of IL-17A AS, nr-axSpA, PSO, PsA <th>ALLENDIA</th> <th>Mechanism of Action</th> <th>Examples of</th>	ALLENDIA	Mechanism of Action	Examples of		
Adalimumab SC Products (Humira®, biosimilars) Inhibition of TNF AS, CD, JIA, PsO, PsA, RA, UC Cimzia® (certolizumab pegol SC injection) Inhibition of TNF AS, CD, nr-axSpA, PsO, PsA, RA CC Cimzia® (certolizumab pegol SC injection) Inhibition of TNF AS, CD, nr-axSpA, PsO, PsA, RA CC Infliximab-dryb SC injection) Inhibition of TNF AS, CD, PsO, PsA, RA, UC Infliximab-dryb SC injection Inhibition of TNF AS, CD, PsO, PsA, RA, UC Infliximab IV Products (Remicade®, biosimilars) Inhibition of TNF SC formulation: AS, PsA, RA, UC Infliximab IV inflixion, tocilizumab SC Inhibition of TNF SC formulation: AS, PsA, RA, UC Infliximab IV inflixion, tocilizumab SC Inhibition of IL-6 SC formulation: PJIA, RA, SJIA Normulation: PJIA, PsA, RA CCD20-directed cytolytic antibody Ra Normulation: PJIA, PsA, RA CCD20-directed cytolytic antibody Normulation: PJIA, PsA, RA Normulation: PJIA, PsA, PsA No	D' I '		Inflammatory Indications*		
Cimzia® (certolizumab pegol SC injection) Inhibition of TNF AS, CD, n-axSpA, PsO, PsA, RA Etanercept SC Products (Embrel®, biosimilars) Inhibition of TNF AS, JIA, PsO, PsA Zymfentra® (infliximab-tylyb SC injection) Inhibition of TNF CD UC Infliximab IV Products (Remicade®, biosimilars) Inhibition of TNF AS, CD, PsO, PsA, RA, UC Simponi®, Simponi® Aria™ (golimumab SC injection) Inhibition of TNF AS C formulation: AS, PsA, RA, UC Simponi®, Simponi® Aria™ (golimumab SC injection) Inhibition of IL-6 SC formulation: PJIA, PsA, RA Actemra® (tocilizumab IV infusion, tocilizumab SC injection) Inhibition of IL-6 RA, PMR Orencia® (sabtacept IV infusion, abatacept SC injection) Inhibition of IL-6 RA, PMR Rituximab IV Products (Rituxan®, biosimilars) CD20-directed cytolytic antibody RA Kineret® (anakinra SC injection) Inhibition of IL-12/3 SC formulation: JIA, PsA, RA Vi infusion Inhibition of IL-17A PsO Bimzelx® (ustekinumab SC injection) Inhibition of IL-17A PsO Bimzelx® (secukinumab SC injection) Inhibition of IL-17A PsO Skyrizi® (risankizumab-rzaa IV infusion) Inhibition of IL-17A	0	T 1 T 1 CODE	La CD HA DO DA DA HG		
Etanercept SC Products (Enbrel®, biosimilars)					
Zymfentra® (infliximab-dyyb SC injection)					
Infliximab IV Products (Řemicade®, biosimilars) Inhibition of TNF Simponi®, Aria™ (golimumab SC injection, golimumab IV infusion, tocilizumab SC injection) Inhibition of IL-6 SC formulation: AS, PJA, RA, UC IV formulation: AS, PJA, RA, RA, UC IV formulation: AS, PJA, RA, RA, SIIA IV formulation: PJIA, RA, SJIA IV formulation: PJIA, PSA, RA IV formulation: JIA, PSA, RA IV formulation: D, UC IV infusion IV formulation: JIA, PSA, RA IV formulation: CD, PSO, PSA, UC IV formulation: CD, UC IV formulation: AS, ERA, RA IV formulation: AS, ERA, RA IV formulation: AS, ERA, RA IV formulation: CD, UC IV formulation: CD					
Simponi®, Simponi® Aria™ (golimumab SC injection, golimumab IV infusion) Inhibition of TNF SC formulation: AS, PsA, RA, UC IV formulation: AS, PIIA, PsA, RA Acteura® (scrilumab IV infusion, tocilizumab SC injection) Inhibition of IL-6 SC formulation: AS, PIIA, RA, SIIA IV formulation: PIIA, PSA, RA IV formulation: PIIA, PSA, PSO, PSA IV formulation: PIIA, PSA, PSO, PSA IV fo	Zymfentra® (infliximab-dyyb SC injection)	Inhibition of TNF			
injection, golimumab IV infusion) Actemra® (tocilizumab IV infusion, tocilizumab SC injection) Inhibition of IL-6 Nevzara® (sarilumab SC injection) Inhibition of IL-10 Inhibition of IL-10 Inhibition of IL-11 Inhibition of IL-12/23 Inhibition of IL-17RA Inhibition of IL-1		Inhibition of TNF			
Actemra® (tocilizumab IV infusion, tocilizumab SC injection) Inhibition of IL-6 SC formulation: PJIA, RA, SJIA IV formulation: JIA, PSA, RA Kilara® (askirama SC injection) Inhibition of IL-1 JIA, RA SC formulation: JIA, PSA, RA RA Stelara® (ustekinumab SC injection) Inhibition of IL-12/23 SC formulation: CD, PSO, PSA, UC SC formulation: CD, UC PSO Slilq™ (birdadizumab-bzxx SC injection) Inhibition of IL-17A and IL-17A PSO SC formulation: AS, RFA, nr-axSpA, PSO, PSA IV formulation: AS, nr-axSpA, PSO, PSA IV formulation: AS, nr-axSpA, PSO, PSA IN formulation: CD, PSO, PSA IN formulation: CD, PSO, PSA, PSO SC formulation: CD, UC SC formulation: CD, UC	Simponi®, Simponi® Aria™ (golimumab SC	Inhibition of TNF	SC formulation: AS, PsA, RA, UC		
injection) Kevzara® (sarilumab SC injection) Orencia® (abatacept IV infusion, abatacept SC injection) Rituximab IV Products (Rituxan®, biosimilars) Kineret® (anakinra SC injection) Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Bimzelx® (bimekizumab-bkzx SC injection) Stelara® (stekinumab SC injection) Bimzelx® (bimekizumab SC injection) Inhibition of IL-17A and IL-17F Cosentyx® (secukinumab SC injection) Inhibition of IL-17A and IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-13 Sc formulation: CD, PsO, PsA, UC IV formulation: AS, ERA, nr-axSpA, PsO, PsA III Inhibition of IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 Sc formulation: AS, ERA, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 Sc formulation: AS, ERA, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 Sc formulation: OD, PsA, PsO IV formulation: DD, PsA, PsO IV formulation: CD, PsA, PsO Inhibition of IL-23 PsO Sc formulation: CD, UC Oral Therapies/Targeted Synthetic DMARDs Olumiant® (baricitinib tablets) Inhibition of JAK pathways Na, PJIA, PsA, UC			IV formulation: AS, PJIA, PsA, RA		
Kevzara® (sarilumab SC injection) Inhibition of IL-6 RA, PMR Orencia® (abatacept IV infusion, abatacept SC injection) T-cell costimulation modulator SC formulation: JIA, PSA, RA Rituximab IV Products (Rituxan®, biosimilars) CD20-directed cytolytic antibody RA Kineret® (anakinra SC injection) Inhibition of IL-1 JIA^*, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-12/23 SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC Sliliq™ (brodalumab SC injection) Inhibition of IL-17RA PsO Bimzelx® (bimekizumab-bkzx SC injection) Inhibition of IL-17A and IL-17F SC formulation: AS, ERA, nr-axSpA, PsO, PsA Cosentyx® (secukinumab SC injection) Inhibition of IL-17A and IL-17A SC formulation: AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asm SC injection) Inhibition of IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asm SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa IV infusion) Inhibition of IL-23 PsO Termfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of	Actemra® (tocilizumab IV infusion, tocilizumab SC	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA		
Orencia® (abatacept IV infusion, abatacept SC injection) T-cell costimulation modulator SC formulation: JIA, PSA, RA Rituximab IV Products (Rituxan®, biosimilars) CD20-directed cytolytic antibody RA Kineret® (anakinra SC injection) Inhibition of IL-1 JIA^*, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-12/23 SC formulation: CD, PsO, PsA, UC IV infusion Inhibition of IL-17RA PsO Bimzelx® (bimekizumab-bkzx SC injection) Inhibition of IL-17A and IL-17F PsO Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A and IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asm SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa IV infusion) Inhibition of IL-23 PsO Integrin receptor antagonis SC formulation: CD, PSA, PsO psA Integrin receptor antagonis SC formulation: CD, UC Temfya™ (uselkumab SC injection) Inhibition of IL-23 PsO Integrin receptor antagonis SC formulation: CD, UC Tormlya™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of JAK pathways SC formulation: CD, UC Tormlya™ (vedolizumab			IV formulation: PJIA, RA, SJIA		
Orencia® (abatacept IV infusion, abatacept SC injection) T-cell costimulation modulator SC formulation: JIA, PSA, RA Rituximab IV Products (Rituxan®, biosimilars) CD20-directed cytolytic antibody RA Kineret® (anakinra SC injection) Inhibition of IL-1 JIA^*, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-12/23 SC formulation: CD, PsO, PsA, UC IV infusion Inhibition of IL-17RA PsO Bimzelx® (bimekizumab-bkzx SC injection) Inhibition of IL-17A and IL-17F PsO Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A and IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asm SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa IV infusion) Inhibition of IL-23 PsO Integrin receptor antagonis SC formulation: CD, PSA, PsO psA Integrin receptor antagonis SC formulation: CD, UC Temfya™ (uselkumab SC injection) Inhibition of IL-23 PsO Integrin receptor antagonis SC formulation: CD, UC Tormlya™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of JAK pathways SC formulation: CD, UC Tormlya™ (vedolizumab	Kevzara® (sarilumab SC injection)	Inhibition of IL-6	RA, PMR		
CD20-directed cytolytic antibody RA	Orencia® (abatacept IV infusion, abatacept SC	T-cell costimulation	SC formulation: JIA, PSA, RA		
Kineret® (anakinra SC injection) Inhibition of IL-1 JIA^, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-12/23 SC formulation: CD, PsO, PsA, UC Siliq™ (brodalumab SC injection) Inhibition of IL-17RA PsO Bimzelx® (bimekizumab-bkzx SC injection) Inhibition of IL-17A PsO Bimzelx® (secukinumab SC injection) Inhibition of IL-17A SC formulation: AS, ERA, nrascpA, PsO, PsA Cosentyx® (secukinumab SC injection) Inhibition of IL-17A SC formulation: AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa SC injection) Inhibition of IL-23 PsO Iremfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of IL-23 PsO Otezla® (apremilast tablets) Inhibition of JAK pathways PsO, PsA Olumiant® (baricitinib tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Xeljanz® (tofacitinib tablets)<	injection)	modulator	IV formulation: JIA, PsA, RA		
Kineret® (anakinra SC injection) Inhibition of IL-1 JIA^, RA Stelara® (ustekinumab SC injection, ustekinumab IV infusion) Inhibition of IL-12/23 SC formulation: CD, PsO, PsA, UC Siliq™ (brodalumab SC injection) Inhibition of IL-17RA PsO Bimzelx® (bimekizumab-bkzx SC injection) Inhibition of IL-17A PsO Bimzelx® (secukinumab SC injection) Inhibition of IL-17A SC formulation: AS, ERA, nrascpA, PsO, PsA Cosentyx® (secukinumab SC injection) Inhibition of IL-17A SC formulation: AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa SC injection) Inhibition of IL-23 PsO Iremfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of IL-23 PsO Otezla® (apremilast tablets) Inhibition of JAK pathways PsO, PsA Olumiant® (baricitinib tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Xeljanz® (tofacitinib tablets)<	Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic	RA		
Stelara® (ustekinumab SC injection, ustekinumab IV infusion)	,	antibody			
IV infusion) Siliq™ (brodalumab SC injection) Bimzelx® (bimekizumab-bkzx SC injection) Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A and IL-17F Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A SC formulation: AS, ERA, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA IV formulation: CD, PSA IV formulation: CD, PSA, PsO Skyrizi® (risankizumab-asmn SC injection) Inhibition of IL-23 Sc formulation: CD, PSA, PsO IV formulation: CD Tremfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Integrin receptor antagonist SC injection) Inhibition of IL-23 SC formulation: CD, PSA, PsO IV formulation: CD TV formulation: CD, UC TV formulation: D, UC TV fo	Kineret® (anakinra SC injection)	Inhibition of IL-1			
IV infusion) Siliq™ (brodalumab SC injection) Bimzelx® (bimekizumab-bkzx SC injection) Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A and IL-17F Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A SC formulation: AS, ERA, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA IV formulation: CD, PSA IV formulation: CD, PSA, PsO Skyrizi® (risankizumab-asmn SC injection) Inhibition of IL-23 Sc formulation: CD, PSA, PsO IV formulation: CD Tremfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Integrin receptor antagonist SC injection) Inhibition of IL-23 SC formulation: CD, PSA, PsO IV formulation: CD TV formulation: CD, UC TV formulation: D, UC TV fo	Stelara® (ustekinumab SC injection, ustekinumab	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC		
Inhibition of IL-17A and IL-17F SC formulation: AS, ERA, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsO			IV formulation: CD, UC		
and IL-17F Cosentyx® (secukinumab SC injection, secukinumab IV infusion) Inhibition of IL-17A SC formulation: AS, ERA, nr-axSpA, PsO, PsA Taltz® (ixekizumab SC injection) Inhibition of IL-17A AS, nr-axSpA, PsO, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 PsO Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion) Inhibition of IL-23 SC formulation: CD, PSA, PsO Tremfya™ (guselkumab SC injection) Inhibition of IL-23 PsO Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Integrin receptor antagonist SC formulation: UC SC formulation: UC Otral Therapies/Targeted Synthetic DMARDs Inhibition of PDE4 PsO, PsA Otezla® (apremilast tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways RA Rinvoq® (upadacitinib extended-release tablets) Inhibition of TYK2 PsO Sotyktu™ (deucravacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	Siliq [™] (brodalumab SC injection)	Inhibition of IL-17RA	PsO		
Cosentyx® (secukinumab SC injection, secukinumab IV infusion)Inhibition of IL-17ASC formulation: AS, ERA, nr-axSpA, PsO, PsASC formulation: AS, nr-axSpA, PsO, PsAIV formulation: AS, nr-axSpA, PsO, PsAIlumya™ (tildrakizumab-asmn SC injection)Inhibition of IL-17AAS, nr-axSpA, PsO, PsASkyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)Inhibition of IL-23PsOTremfya™ (guselkumab SC injection)Inhibition of IL-23PsOEntyvio™ (vedolizumab IV infusion, vedolizimab SC injection)Integrin receptor antagonist Integrin receptor antagonist Inhibition of PDE4PsO, PsASC injection)SC formulation: UCOral Therapies/Targeted Synthetic DMARDsInhibition of PDE4PsO, PsACibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of TYK2PsOSotyktu™ (deucravacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UCXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	Bimzelx® (bimekizumab-bkzx SC injection)	Inhibition of IL-17A	PsO		
secukinumab IV infusion) axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA IV formulation: CD, PsA IV formulation: CD IV formulation: CD, UC IV formulation: CD, UC					
Taltz® (ixekizumab SC injection) Inhibition of IL-17A RS, nr-axSpA, PsA Ilumya™ (tildrakizumab-asmn SC injection) Inhibition of IL-23 Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion) Tremfya™ (guselkumab SC injection) Inhibition of IL-23 Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Inhibition of IL-23 Integrin receptor antagonist SC formulation: CD To formulation: UC IV formulation: UC IV formulation: CD, UC Oral Therapies/Targeted Synthetic DMARDs Otezla® (apremilast tablets) Inhibition of PDE4 Cibinqo™ (abrocitinib tablets) Inhibition of JAK pathways Olumiant® (baricitinib tablets) Inhibition of JAK pathways Rinvoq® (upadacitinib extended-release tablets) Inhibition of TYK2 Sotyktu™ (deucravacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	Cosentyx® (secukinumab SC injection,	Inhibition of IL-17A	SC formulation: AS, ERA, nr-		
Taltz® (ixekizumab SC injection)Inhibition of IL-17AAS, nr-axSpA, PsO, PsAIlumya™ (tildrakizumab-asmn SC injection)Inhibition of IL-23PsOSkyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)Inhibition of IL-23SC formulation: CD, PSA, PsOTremfya™ (guselkumab SC injection)Inhibition of IL-23PsOEntyvio™ (vedolizumab IV infusion, vedolizimab SC injection)Integrin receptor antagonistSC formulation: UCOral Therapies/Targeted Synthetic DMARDsInhibition of PDE4PsO, PsAOtezla® (apremilast tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of TYK2PsOSotyktu™ (deucravacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UCXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	secukinumab IV infusion)				
Ilumya™ (tildrakizumab-asmn SC injection)Inhibition of IL-23PsOSkyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)Inhibition of IL-23SC formulation: CD, PSA, PsOTremfya™ (guselkumab SC injection)Inhibition of IL-23PsOEntyvio™ (vedolizumab IV infusion, vedolizimab SC injection)Integrin receptor antagonistSC formulation: UCOral Therapies/Targeted Synthetic DMARDsOtezla® (apremilast tablets)Inhibition of PDE4PsO, PsACibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC			IV formulation: AS, nr-axSpA, PsA		
Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)Inhibition of IL-23SC formulation: CD, PSA, PsOTremfya™ (guselkumab SC injection)Inhibition of IL-23PsOEntyvio™ (vedolizumab IV infusion, vedolizimab SC injection)Integrin receptor antagonistSC formulation: UC IV formulation: CD, UCOral Therapies/Targeted Synthetic DMARDsInhibition of PDE4PsO, PsACibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC			AS, nr-axSpA, PsO, PsA		
risankizumab-rzaa IV infusion) Tremfya™ (guselkumab SC injection) Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Integrin receptor antagonist SC injection) Oral Therapies/Targeted Synthetic DMARDs Otezla® (apremilast tablets) Inhibition of PDE4 Cibinqo™ (abrocitinib tablets) Inhibition of JAK pathways Olumiant® (baricitinib tablets) Inhibition of JAK pathways Rinvoq® (upadacitinib extended-release tablets) Sotyktu™ (deucravacitinib tablets) Inhibition of TYK2 Sotyktu™ (deucravacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	Ilumya [™] (tildrakizumab-asmn SC injection)		PsO		
Tremfya™ (guselkumab SC injection)Inhibition of IL-23PsOEntyvio™ (vedolizumab IV infusion, vedolizimab SC injection)Integrin receptor antagonistSC formulation: UCOral Therapies/Targeted Synthetic DMARDsInhibition of PDE4PsO, PsAOtezla® (apremilast tablets)Inhibition of JAK pathwaysADCibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysRAOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	Skyrizi® (risankizumab-rzaa SC injection,	Inhibition of IL-23	SC formulation: CD, PSA, PsO		
Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection) Integrin receptor antagonist SC formulation: UC IV formulation: CD, UC Oral Therapies/Targeted Synthetic DMARDs Inhibition of PDE4 PsO, PsA Otezla® (apremilast tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways RA Rinvoq® (upadacitinib extended-release tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Sotyktu™ (deucravacitinib tablets) Inhibition of TYK2 PsO Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	,		IV formulation: CD		
SC injection) IV formulation: CD, UC Oral Therapies/Targeted Synthetic DMARDs Otezla® (apremilast tablets) Inhibition of PDE4 PsO, PsA Cibinqo™ (abrocitinib tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways RA Rinvoq® (upadacitinib extended-release tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Sotyktu™ (deucravacitinib tablets) Inhibition of TYK2 PsO Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC			PsO		
Oral Therapies/Targeted Synthetic DMARDs Otezla® (apremilast tablets) Inhibition of PDE4 PsO, PsA Cibinqo™ (abrocitinib tablets) Inhibition of JAK pathways AD Olumiant® (baricitinib tablets) Inhibition of JAK pathways RA Rinvoq® (upadacitinib extended-release tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Sotyktu™ (deucravacitinib tablets) Inhibition of TYK2 PsO Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	Entyvio [™] (vedolizumab IV infusion, vedolizimab	Integrin receptor antagonist	SC formulation: UC		
Otezla® (apremilast tablets)Inhibition of PDE4PsO, PsACibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	SC injection)		IV formulation: CD, UC		
Otezla® (apremilast tablets)Inhibition of PDE4PsO, PsACibinqo™ (abrocitinib tablets)Inhibition of JAK pathwaysADOlumiant® (baricitinib tablets)Inhibition of JAK pathwaysRARinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	Oral Therapies/Targeted Synthetic DMARDs				
Olumiant® (baricitinib tablets) Inhibition of JAK pathways RA Rinvoq® (upadacitinib extended-release tablets) Inhibition of JAK pathways AD, AS, nr-axSpA, RA, PsA, UC Sotyktu™ (deucravacitinib tablets) Inhibition of TYK2 PsO Xeljanz® (tofacitinib tablets) Inhibition of JAK pathways RA, PJIA, PsA, UC	Otezla® (apremilast tablets)	Inhibition of PDE4	PsO, PsA		
Rinvoq® (upadacitinib extended-release tablets)Inhibition of JAK pathwaysAD, AS, nr-axSpA, RA, PsA, UCSotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	Cibinqo™ (abrocitinib tablets)	Inhibition of JAK pathways	AD		
Sotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC		Inhibition of JAK pathways	RA		
Sotyktu™ (deucravacitinib tablets)Inhibition of TYK2PsOXeljanz® (tofacitinib tablets)Inhibition of JAK pathwaysRA, PJIA, PsA, UC	Rinvoq® (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, UC		
		Inhibition of TYK2			
		Inhibition of JAK pathways	RA, PJIA, PsA, UC		
initiation of vital painting of the first oc	Xeljanz® XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC		

*Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn's disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; PMR – Polymyalgia rheumatic; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; TYK2 – Tyrosine kinase 2.